Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do patients undergoing percutaneous coronary intervention benefit from clopidogrel pretreatment?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 12–13 (2006)Cite this article

boxed-textSabatine MS et al. (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI–CLARITY study. JAMA 294: 1224–1232

Patients with acute coronary syndromes—whether non-STEMI or STEMI acute coronary syndromes after thrombolysis, or chronic coronary disease—should be pretreated with clopidogrel

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sabatine MS et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

    Article  CAS  Google Scholar 

  2. Mehta SR et al. (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527–533

    Article  CAS  Google Scholar 

  3. Steinhubl SR et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411–2420

    Article  CAS  Google Scholar 

  4. Beinart SC et al. (2005) Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 46: 761–769

    Article  CAS  Google Scholar 

  5. Weintraub WS et al. (2005) Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 45: 838–845

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Director of the Division of Cardiology and Director of the Christiana Center for Outcomes Research at Christiana Care Health Services, Newark, DE, USA

    William S Weintraub

Authors
  1. William S Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William S Weintraub.

Ethics declarations

Competing interests

WS Weintraub has received grants from Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weintraub, W. Do patients undergoing percutaneous coronary intervention benefit from clopidogrel pretreatment?. Nat Rev Cardiol 3, 12–13 (2006). https://doi.org/10.1038/ncpcardio0398

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0398

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing